3results about How to "Non-addictive" patented technology

This invention discloses a nicotine-capturing smoking cessation drug composition based on molecular configuration matching, belonging to the field of smoking cessation drug technology. The drug consists of three organic functional molecules screened by molecular structure (each molecule has a specific configuration, see Figure 2) that self-assemble in a specific molar ratio under human physiological conditions to form a three-dimensional molecular cage. This molecular cage, through precise adaptation of its internal cavity configuration to the chair conformation of nicotine molecules (the configuration after binding is shown in Figure 3), specifically recognizes and encapsulates nicotine molecules, preventing them from crossing the blood-brain barrier and entering the brain by increasing molecular weight and enhancing polarity. This blocks the nicotine addiction reward pathway at its source, thereby eliminating nicotine addiction and physiological dependence. The drug of this invention only acts in the peripheral circulation, does not enter the central nervous system, does not act on brain nerve receptors, has no psychotropic side effects, and is non-addictive. The molecular cage-nicotine complex can be normally metabolized and completely excreted from the body. This invention, with precise molecular configuration matching as its core innovation, has a novel mechanism, extremely high safety, and gentle withdrawal, effectively reducing relapse rates. It is suitable for various nicotine-dependent populations and has extremely high clinical translational and patent protection value.

The application discloses a transdermal patch containing phosphodiesterase 7 inhibitors and application thereof, and relates to the technical field of external drug preparations. The transdermal patch comprises a backing layer, a drug-containing functional layer and an anti-adhesion protective layer. The drug-containing functional layer contains phosphodiesterase 7 inhibitors and pharmaceutically acceptable adjuvants. The phosphodiesterase 7 inhibitors are selected from OMS527 or 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one. The transdermal patch can be used alone or in combination with nicotine. In vitro transdermal experiments show that the cumulative release rate reaches 70% to 96% in 24 hours. Skin irritation tests show that the Draize score is less than or equal to 0.4, belonging to extremely slight irritation. Animal efficacy experiments show that the patch can significantly inhibit nicotine self-administration behavior, prevent relapse and relieve withdrawal symptoms. The transdermal patch has novel action mechanism, no addiction, long-lasting drug efficacy, safe and convenient use, and can be used for smoking cessation or relieving nicotine withdrawal symptoms.

The invention discloses venenum bufonis, venenum bufonis active ingredients and application of a venenum bufonis active ingredient composition in relieving inflammatory pain and bone cancer pain, and belongs to the technical field of venenum bufonis analgesic active ingredient research. It is found that the venenum bufonis medicinal material can relieve inflammatory pain and bone cancer pain, and it is clear that the main active ingredients of the venenum bufonis medicinal material are cinobufagin and resibufogenin; the cinobufagin and the resibufogenin have a good analgesic effect in a certain ratio range, inflammation pain can be relieved when the mass ratio of the cinobufagin to the resibufogenin is 4: 5-5: 1, and bone cancer pain can be relieved when the mass ratio of the cinobufagin to the resibufogenin is 1: 10-5: 1. The active ingredients cinobufagin and resibufogenin are enlightenment that cinobufagin and resibufogenin can become substitutes of endangered medicinal material venenum bufonis for relieving inflammation pain and bone cancer pain; in addition, it is found for the first time that the analgesic effect of resibufogenin is similar to that of morphine, no addiction exists, and it is prompted that resibufogenin is expected to be developed into a novel analgesic drug.